{
    "root": "4243fa30-9538-4788-a6ac-a9db774d3213",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "testosterone",
    "value": "20250304",
    "ingredients": [
        {
            "name": "TESTOSTERONE",
            "code": "3XMK78S47O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17347"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "OCTISALATE",
            "code": "4X49Y0596W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11062"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        }
    ],
    "indications": {
        "text": "testosterone topical solution indicated replacement therapy males conditions associated deficiency absence endogenous testosterone . \u2022 primary hypogonadism ( congenital acquired ) : testicular failure due conditions cryptorchidism , bilateral torsion , orchitis , vanishing testis syndrome , orchiectomy , klinefelter \u2019 syndrome , chemotherapy , toxic damage alcohol heavy metals . men usually low serum testosterone concentrations gonadotropins ( fsh , lh ) normal range . \u2022 hypogonadotropic hypogonadism ( congenital acquired ) : gonadotropin luteinizing hormone-releasing hormone ( lhrh ) deficiency pituitary-hypothalamic injury tumors , trauma , radiation . men low testosterone serum concentrations gonadotropins normal low range . limitations : \u2022safety efficacy testosterone topical solution men \u201c age-related hypogonadism \u201d ( also referred \u201c late-onset hypogonadism \u201d ) established . \u2022safety efficacy testosterone topical solution males < 18 years old established [ ( 8.4 ) ] .",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            },
            {
                "text": "cryptorchidism (DOID:11383)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11383"
            },
            {
                "text": "orchitis (DOID:2518)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2518"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "hypogonadotropic hypogonadism (DOID:0090070)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0090070"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "prior initiating testosterone topical solution , confirm diagnosis hypogonadism ensuring serum testosterone concentrations measured morning least two separate days serum testosterone concentrations normal range .",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "\u2022testosterone topical solution contraindicated men carcinoma breast known suspected carcinoma prostate [ precaution ( 5.1 ) ] . \u2022testosterone topical solution contraindicated women , may become pregnant , breastfeeding . testosterone topical solution may cause fetal harm administered pregnant woman . testosterone topical solution may cause serious nursing infants . pregnant woman exposed testosterone topical solution , apprised potential hazard fetus . [ ( 8.1 , 8.3 ) ] .",
    "indications_original": "Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.\n                  \n                     \n                        \u2022\n                        Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter\u2019s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (FSH, LH) above the normal range.\n                     \n                        \u2022\n                        Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.\n                  \n                  \n                     Limitations of use:\n                  \n                  \n                     \n                        \u2022Safety and efficacy of Testosterone Topical Solution in men with \u201cage-related hypogonadism\u201d (also referred to as \u201clate-onset hypogonadism\u201d) have not been established.\n                     \n                        \u2022Safety and efficacy of Testosterone Topical Solution in males <18 years old have not been established [see Use in Specific Populations (8.4)].",
    "contraindications_original": "Prior to initiating Testosterone Topical Solution, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.",
    "adverseReactions_original": "\u2022Testosterone Topical Solution is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precaution (5.1)].\n                     \n                        \u2022Testosterone Topical Solution is contraindicated in women who are, or who may become pregnant, or who are breastfeeding. Testosterone Topical Solution may cause fetal harm when administered to a pregnant woman. Testosterone Topical Solution may cause serious adverse reactions in nursing infants. If a pregnant woman is exposed to Testosterone Topical Solution, she should be apprised of the potential hazard to the fetus. [See Use in Specific Populations (8.1, 8.3)].",
    "drug": [
        {
            "name": "testosterone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17347"
        }
    ]
}